7-Hydroxystaurosporine
- Generic Name
- 7-Hydroxystaurosporine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C28H26N4O4
- CAS Number
- 112953-11-4
- Unique Ingredient Identifier
- 7BU5H4V94A
- Associated Conditions
- -
- Associated Therapies
- -
UCN-01, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00042861
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
Phase 1
Completed
- Conditions
- Advanced Adult Primary Liver CancerRecurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal CavityRecurrent Extrahepatic Bile Duct CancerRecurrent Gallbladder CancerRecurrent Gastric CancerRecurrent Gastrointestinal Carcinoid TumorRecurrent Inverted Papilloma of the Paranasal Sinus and Nasal CavityCarcinoma of the AppendixGastrointestinal Stromal TumorEstrogen Receptor-negative Breast Cancer
- Interventions
- Drug: 7-hydroxystaurosporineDrug: irinotecan hydrochlorideOther: diagnostic laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 41
- Registration Number
- NCT00031681
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia
Phase 1
Completed
- Conditions
- LymphomaLeukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00019838
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸NCI - Center for Cancer Research, Bethesda, Maryland, United States
A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms
Phase 1
Completed
- Conditions
- Breast CancerProstatic NeoplasmLymphomaNeoplasm
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 51
- Registration Number
- NCT00001444
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath